Review – Neuro-urologyA Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder☆
Introduction
Overactive bladder (OAB) is a highly prevalent condition [1], [2] with enormous related costs per year [3], [4]. First-line treatments for OAB include lifestyle modifications, behavioral therapy, pelvic floor muscle training, and bladder training. Antimuscarinic drugs are the first-line drug therapy, while other therapeutic options, such as botulinum toxin injection, neuromodulation, or surgical interventions are used in a smaller percentage of patients who are non-responders to drug therapies [5], [6].
Several antimuscarinic drugs are on the market, including oxybutynin, tolterodine, propiverine, trospium, the recently released solifenacin and darifenacin, and fesoterodine, which was the last one to receive the European Medicines Evaluation Agency (EMEA) marketing authorization in 2006. Moreover, some drugs such as oxybutynin, tolterodine, propiverine, or trospium are available both in immediate-release (IR) and extended-release (ER) formulations, while oxybutynin is also available in a sustained-delivery patch for transdermal administration [7]. Two meta-analyses evaluated the efficacy of the anticholinergic drugs in comparison to placebo, showing that the use of these drugs results in statistically significant improvements in symptoms and quality of life [8], [9]. To date, however, the clinical data available on the active comparisons of different drugs, formulations, and routes of administration are more limited. Specifically, a Cochrane meta-analysis based on a systematic review performed in January 2002 demonstrated that tolterodine was as effective as, but better tolerated than, oxybutynin; moreover, ER formulations of oxybutynin and/or tolterodine were shown to cause a lower risk of dry mouth compared to the IR formulations. Comparing head-to-head the ER formulations, xerostomia was less common in those patients receiving tolterodine [10]. In a more recent meta-analysis which mainly focused on placebo-controlled trials, Chapple et al reported some data on the trials of drugs which provided active drug controls. Solifenacin was shown to be more effective than tolterodine IR in terms of reduction of both urgency episodes and number of micturitions, while oxybutynin ER was shown to be more effective than tolterodine ER, in terms of reduction of incontinence episodes. Finally, oxybutynin IR 15 mg once daily, solifenacin 5 mg once daily, and solifenacin 10 mg once daily were more effective than tolterodine IR in increasing the volume voided per micturitions [8].
The purpose of the present systematic review and meta-analysis was to evaluate all the clinical data derived from randomized controlled trials in order to assess the efficacy and safety of different doses, formulations, and routes of administration of the currently available anticholinergic drugs, as well as head-to-head comparisons of different drugs.
Section snippets
Methods
The systematic review of the literature was performed in August 2007 using the Medical Literature Analysis and Retrieval System Online (U.S. National Library of Medicine's life science database; MEDLINE), the Excerpta Medica database (EMBASE), and Thomson-Reuters’ Web of Science. The MEDLINE search employed a complex search strategy, including both “MeSH” (Medical Subject Heading) and “free text” protocols. Specifically, the MeSH search was conducted by combining the following terms retrieved
Results
984 records were retrieved by searching MEDLINE: 910 records were retrieved from EMBASE, and 669 records were retrieved from Web of Science. The studies evaluating lower urinary tract storage symptoms in patients with bladder-outlet obstructions, papers evaluating neurogenic OAB or OAB in children, phase I studies, post-hoc analyses of RCTs, and duplicate publications were excluded. We finally identified 50 RCTs and three pooled analyses of RCTs for inclusion in this review (Fig. 1).
Discussion
Due to the large number of drugs available on the market, the selection of the most appropriate one for every single patient might be quite a complex task. The choice of the first drug to be used, the selection of the most appropriate dosage, formulation, and route of administration, the criteria for selection of a second anticholinergic drug in case of insufficient efficacy or intolerable adverse events, and, finally, costs are some of the most important issues that should be evaluated.
The
Conclusions
Many of the available RCTs in the field of muscarinic receptor antagonists for overactive bladder are of good methodological quality. ER formulations should be preferred to the IR formulations due to the more favorable profile of efficacy and adverse events. With regard to IR formulations, dose escalation might yield some improvements in the efficacy, but at the cost of a significant increase in the rate of adverse events. More clinical studies are needed to determine which of the available
References (68)
- et al.
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study
Eur Urol
(2006) Advancing the management of overactive bladder: new data, new directions
Eur Urol Suppl
(2007)- et al.
The current and future burden and cost of overactive bladder in five European countries
Eur Urol
(2006) - et al.
The economic costs of overactive bladder in Germany
Eur Urol
(2007) - et al.
Critical evaluation of the efficacy and safety of anticholinergics in overactive bladder
Eur Urol Suppl
(2007) Long-term management of overactive bladder with antimuscarinic agents
Eur Urol Suppl
(2007)- et al.
The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis
Eur Urol
(2005) - et al.
Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence
Obstet Gynecol
(2000) - et al.
A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence
Clin Ther
(2004) - et al.
Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity
J Urol
(1999)
Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder
Eur J Obstet Gynecol Reprod Biol
Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder
Urology
Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder
J Urol
Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist
Eur Urol
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder
Eur Urol
Efficacy, safety, and tolerability of fesoterodine for overactive bladder syndrome
J Urol
Once-daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence
Urology
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study
Mayo Clin Proc
Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial
J Urol
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial
Mayo Clin Proc
Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity
Eur Urol
Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder
Eur Urol
A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial
Eur Urol
Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg
Eur Urol
Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo
J Urol
A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence
J Urol
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence
Urology
Transdermal oxybutynin: sticking to the facts
Eur Urol
Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials
Eur Urol
Validation of an index of the quality of review articles
J Clin Epidemiol
Muscarinic receptor antagonists for overactive bladder
BJU Int
Randomised controlled trials
Cited by (226)
Prevalence of overactive bladder among overweight and obese women: A prospective cross-sectional cohort study
2024, European Journal of Obstetrics and Gynecology and Reproductive BiologyTwenty six-week repeat dose oral rat toxicity study of cizolirtine, a substance-P and calcitonin gene-related peptide release modulator
2021, Regulatory Toxicology and PharmacologyFirst-line treatment for non-neurogenic overactive bladder
2020, Progres en UrologieEvaluation and Treatment of Overactive Bladder in Women
2020, Mayo Clinic Proceedings
- ☆
Please visit www.eu-acme.org/europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.